收涨100%！这家0收入创新药企要火？

Core Viewpoint - The innovative drug company ViliZhibo, which currently has no revenue and is operating at a loss, has gained significant attention in the Hong Kong stock market amid a bullish trend for innovative drugs [1]. Company Overview - ViliZhibo plans to globally issue 32.0544 million shares, with an initial offering price range of HKD 31.60 to HKD 35.00, resulting in an estimated entry fee of approximately HKD 3,535.3 per lot of 100 shares [3][5]. - The company has a strong lineup of cornerstone investors, including Tencent, E Fund, Zhengxin Valley Capital, and Gao Yi [5]. Financial Performance - For 2023, ViliZhibo reported a revenue of HKD 8.865 million, but it is projected to have no revenue in 2024 and the first quarter of 2025, with net losses of HKD 362 million, HKD 301 million, and HKD 75.367 million respectively [5]. - The company has only one client, BeiGene, from which it received USD 1.3 million in 2023 for a specified bridging study [5]. Market Response - As of July 25, ViliZhibo's stock closed at HKD 70.05, a 100.14% increase from its IPO price of HKD 35.00, indicating strong market demand [1][4]. - The subscription for ViliZhibo's shares exceeded 3,000 times, with a total subscription amount reaching HKD 330 billion, making it the hottest IPO in Hong Kong for July [4].